DOCSLIB.ORG

153 Part 520—Oral Dosage Form New Animal Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
153 Part 520—Oral Dosage Form New Animal Drugs Food and Drug Administration, HHS Pt. 520 PART 520—ORAL DOSAGE FORM 520.420 Chlorothiazide tablets and boluses. 520.434 Chlorphenesin carbamate tablets. NEW ANIMAL DRUGS 520.441 Chlortetracycline powder. 520.443 Chlortetracycline tablets and Sec. boluses. 520.23 Acepromazine. 520.445 Chlortetracycline and 520.28 Acetazolamide. sulfamethazine powder. 520.38 Albendazole oral dosage forms. 520.446 Clindamycin capsules and tablets. 520.38a Albendazole suspension. 520.447 Clindamycin solution. 520.38b Albendazole paste. 520.452 Clenbuterol syrup. 520.43 Afoxolaner. 520.455 Clomipramine tablets. 520.48 Altrenogest. 520.462 Clorsulon drench. 520.62 Aminopentamide. 520.522 Cyclosporine. 520.82 Aminopropazine oral dosage forms. 520.530 Cythioate oral liquid. 520.82a Aminopropazine. 520.531 Cythioate tablets. 520.82b Aminopropazine and neomycin. 520.534 Decoquinate. 520.88 Amoxicillin oral dosage forms. 520.538 Deracoxib. 520.88a Amoxicillin trihydrate film-coated 520.540 Dexamethasone oral dosage forms. tablets. 520.540a Dexamethasone powder. 520.88b Amoxicillin trihydrate for oral sus- 520.540b Dexamethasone tablets and pension. boluses. 520.88c Amoxicillin trihydrate oral suspen- 520.540c Dexamethasone chewable tablets. sion. 520.563 Dexamethasone chewable tablets. 520.88d Amoxicillin trihydrate soluble pow- 520.580 Dichlorophene and toluene. der. 520.581 Dichlorophene tablets. 520.88e Amoxicillin trihydrate boluses. 520.600 Dichlorvos. 520.88f Amoxicillin trihydrate tablets. 520.606 Diclazuril. 520.88g Amoxicillin trihydrate and 520.608 Dicloxacillin. clavulanate potassium film-coated tab- 520.620 Diethylcarbamazine oral dosage lets. forms. 520.88h Amoxicillin trihydrate and 520.622 Diethylcarbamazine citrate oral dos- clavulanate potassium for oral suspen- age forms. sion. 520.622a Diethylcarbamazine citrate tablets. 520.90 Ampicillin oral dosage forms. 520.622b Diethylcarbamazine citrate syrup. 520.90a [Reserved] 520.622c Diethylcarbamazine citrate chew- 520.90b Ampicillin tablets. able tablets. 520.90c Ampicillin capsules. 520.623 Diethylcarbamazine and 520.90d Ampicillin for oral suspension. oxibendazole chewable tablets. 520.90e Ampicillin for soluble powder. 520.645 Difloxacin. 520.90f Ampicillin boluses. 520.666 Dirlotapide. 520.100 Amprolium. 520.763 Dithiazanine oral dosage forms. 520.110 Apramycin sulfate soluble powder. 520.763a Dithiazanine tablets. 520.154 Bacitracin oral dosage forms. 520.763b Dithiazanine powder. 520.154a Bacitracin methylenedisalicylate. 520.763c Dithiazanine iodide and piperazine 520.154b Bacitracin methylenedisalicylate citrate suspension. and streptomycin sulfate powder. 520.766 Domperidone. 520.154c Bacitracin zinc soluble powder. 520.784 Doxylamine. 520.222 Bunamidine hydrochloride. 520.804 Enalapril. 520.246 Butorphanol tablets. 520.812 Enrofloxacin. 520.260 n-Butyl chloride. 520.816 Epsiprantel. 520.284 Cambendazole oral dosage forms. 520.823 Erythromycin. 520.284a Cambendazole suspension. 520.852 Estriol. 520.284b Cambendazole pellets. 520.863 Ethylisobutrazine. 520.284c Cambendazole paste. 520.870 Etodolac. 520.292 Capromorelin. 520.903 Febantel oral dosage forms. 520.301 Caramiphen ethanedisulfonate and 520.903a Febantel paste. ammonium chloride tablets. 520.903b Febantel suspension. 520.302 Carnidazole tablets. 520.903c [Reserved] 520.304 Carprofen. 520.903d Febantel and praziquantel paste. 520.314 Cefadroxil. 520.903e Febantel tablets. 520.370 Cefpodoxime tablets. 520.905 Fenbendazole oral dosage forms. 520.376 Cephalexin. 520.905a Fenbendazole suspension. 520.390 Chloramphenicol oral dosage forms. 520.905b Fenbendazole granules. 520.390a Chloramphenicol tablets. 520.905c Fenbendazole paste. 520.390b Chloramphenicol capsules. 520.905d Fenbendazole powder. 520.390c Chloramphenicol palmitate oral 520.905e Fenbendazole blocks. suspension. 520.928 Firocoxib tablets. 153 VerDate Sep<11>2014 17:54 May 11, 2017 Jkt 241075 PO 00000 Frm 00163 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB Pt. 520 21 CFR Ch. I (4–1–17 Edition) 520.930 Firocoxib paste. 520.1331 Meclofenamic acid tablets. 520.955 Florfenicol. 520.1341 Megestrol. 520.960 Flumethasone. 520.1367 Meloxicam. 520.970 Flunixin. 520.1372 Methimazole. 520.980 Fluoxetine. 520.1380 Methocarbamol. 520.998 Fluralaner. 520.1408 Methylprednisolone. 520.1010 Furosemide. 520.1409 Methylprednisolone and aspirin. 520.1044 Gentamicin sulfate oral dosage 520.1422 Metoserpate hydrochloride. forms. 520.1430 Mibolerone. 520.1044a Gentamicin sulfate oral solution. 520.1441 Milbemycin oxime. 520.1044b Gentamicin sulfate pig pump oral 520.1443 Milbemycin oxime and lufenuron. solution. 520.1445 Milbemycin oxime and 520.1044c Gentamicin sulfate powder. praziquantel. 520.1060 Glucose and glycine. 520.1447 Milbemycin oxime, lufenuron, and 520.1084 Grapiprant. praziquantel tablets. 520.1100 Griseofulvin. 520.1450 Morantel tartrate oral dosage 520.1120 Haloxon oral dosage forms. forms. 520.1120a Haloxon drench. 520.1450a Morantel tartrate bolus. 520.1120b Haloxon boluses. 520.1450b Morantel tartrate cartridge. 520.1130 Hetacillin. 520.1450c Morantel tartrate sustained-re- 520.1156 Imidacloprid. lease trilaminate cylinder/sheet. 520.1157 Iodinated casein. 520.1451 Moxidectin tablets. 520.1158 Iodochlorhydroxyquin. 520.1452 Moxidectin gel. 520.1182 Iron dextran suspension. 520.1453 Moxidectin and praziquantel gel. 520.1189 Itraconazole. 520.1454 Moxidectin solution. 520.1192 Ivermectin paste. 520.1468 Naproxen. 520.1193 Ivermectin tablets and chewables. 520.1484 Neomycin. 520.1194 Ivermectin meal. 520.1510 Nitenpyram. 520.1195 Ivermectin liquid. 520.1604 Oclacitinib. 520.1196 Ivermectin and pyrantel tablets. 520.1615 Omeprazole. 520.1197 Ivermectin sustained-release bolus. 520.1616 Orbifloxacin tablets.. 520.1198 Ivermectin and praziquantel paste. 520.1618 Orbifloxacin suspension. 520.1199 Ivermectin, pyrantel, and 520.1628 Oxfendazole powder and pellets. praziquantel tablets. 520.1629 Oxfendazole paste. 520.1200 Ivermectin, fenbendazole, and 520.1630 Oxfendazole suspension. praziquantel tablets. 520.1631 Oxfendazole and trichlorfon paste. 520.1204 Kanamycin, bismuth subcarbonate, 520.1638 Oxibendazole. activated attapulgite. 520.1660 Oxytetracycline. 520.1242 Levamisole. 520.1660a Oxytetracycline and carbomycin. 520.1242a Levamisole powder. 520.1660b Oxytetracycline hydrochloride 520.1242b Levamisole boluses or oblets. capsules. 520.1242c Levamisole and piperazine. 520.1660c Oxytetracycline hydrochloride 520.1242d Levamisole resinate. tablets/boluses. 520.1242e Levamisole hydrochloride effer- 520.1660d Oxytetracycline powder. vescent tablets. 520.1696 Penicillin. 520.1242f Levamisole gel. 520.1696a [Reserved] 520.1242g Levamisole resinate and famphur 520.1696b Penicillin G powder. paste. 520.1696c Penicillin V powder. 520.1248 Levothyroxine. 520.1696d Penicillin V tablets. 520.1263 Lincomycin. 520.1705 Pergolide. 520.1263a Lincomycin tablets and syrup. 520.1720 Phenylbutazone oral dosage forms. 520.1263b [Reserved] 520.1720a Phenylbutazone tablets and 520.1263c Lincomycin powder. boluses. 520.1265 Lincomycin and spectinomycin 520.1720b Phenylbutazone granules. powder. 520.1720c Phenylbutazone paste. 520.1284 Liothyronine. 520.1720d Phenylbutazone gel. 520.1288 Lufenuron tablets. 520.1720e Phenylbutazone powder. 520.1289 Lufenuron suspension. 520.1760 Phenylpropanolamine. 520.1310 Marbofloxacin. 520.1780 Pimobendan. 520.1315 Maropitant. 520.1802 Piperazine-carbon disulfide complex 520.1320 Mebendazole. oral dosage forms. 520.1326 Mebendazole and trichlorfon oral 520.1802a Piperazine-carbon disulfide com- dosage forms. plex suspension. 520.1326a Mebendazole and trichlorfon pow- 520.1802b Piperazine-carbon disulfide com- der. plex boluses. 520.1326b Mebendazole and trichlorfon paste. 520.1802c Piperazine-carbon disulfide com- 520.1330 Meclofenamic acid granules. plex with phenothiazine suspension. 154 VerDate Sep<11>2014 17:54 May 11, 2017 Jkt 241075 PO 00000 Frm 00164 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB Food and Drug Administration, HHS Pt. 520 520.1803 Piperazine citrate capsules. 520.2260c Sulfamethazine sustained-release 520.1804 Piperazine phosphate capsules. tablets. 520.1805 Piperazine phosphate with thenium 520.2261 Sulfamethazine sodium oral dosage closylate tablets. forms. 520.1806 Piperazine suspension. 520.2261a Sulfamethazine solution. 520.1807 Piperazine. 520.2261b Sulfamethazine powder. 520.1840 Poloxalene. 520.2280 Sulfamethizole and methenamine. 520.1846 Polyoxyethylene (23) lauryl ether 520.2325 Sulfaquinoxaline oral dosage forms. blocks. 520.2325a Sulfaquinoxaline powder and solu- 520.1855 Ponazuril. tion. 520.1860 Pradofloxacin. 520.2325b Sulfaquinoxaline drench. 520.1870 Praziquantel tablets. 520.2330 Sulfisoxazole tablets. 520.1871 Praziquantel and pyrantel. 520.2340 Tepoxalin. 520.1872 Praziquantel, pyrantel pamoate, 520.2345 Tetracycline. and febantel tablets. 520.2345a Tetracycline capsules. 520.1880 Prednisolone. 520.2345b Tetracycline tablets. 520.1900 Primidone. 520.2345c Tetracycline boluses. 520.1920 Prochlorperazine and isopropamide. 520.2345d Tetracycline powder. 520.1921 Prochlorperazine, isopropamide, 520.2345e Tetracycline solution. and neomycin. 520.2345f Tetracycline phosphate complex 520.1962 Promazine. and sodium novobiocin capsules. 520.2345g Tetracycline hydrochloride and so- 520.2002 Propiopromazine. dium novobiocin tablets. 520.2041 Pyrantel pamoate chewable tablets. 520.2345h Tetracycline hydrochloride, so- 520.2042 Pyrantel pamoate tablets. dium novobiocin,
Load more

Recommended publications
  • Bulletin Leading the Fight Against Heartworm Disease
    BULLETIN LEADING THE FIGHT AGAINST HEARTWORM DISEASE SEPTEMBER HEARTWORM 2017 Q&A VOLUME 44 No. 3 Heartworm History: In What Year Was Heartworm First INSIDE THIS ISSUE Treated? Page 4 From the President Page 8 Research Update Abstracts from the Literature Page 14 Heartworm Hotline: Role of Heat Treatment in Diagnostics Page 19 NEW! Best Practices: Minimizing Heartworm Transmission in Relocated Dogs uestions from members, prac- published in the 1998 AHS Symposium 1 titioners, technicians, and the Proceedings. Dr. Roncalli wrote, “The Page 21 Qgeneral public are often submit- first trial to assess the efficacy of a Welcome Our New AHS ted to the American Heartworm Society microfilaricide (natrium antimonyl tar- Student Liaisons (AHS) via our website. Two of our AHS trate) was conducted some 70 years Board members, Dr. John W.McCall and ago (1927) in Japan by S. Itagaki and R. Page 25 Dr. Tom Nelson, provided the resources Makino.2 Fuadin (stibophen), a trivalent In the News: Surgeons to answer this question: In What Year antimony compound, was tested, intra- Remove a Heartworm from Was Heartworm First Treated? venously, as a microfilaricide by Popescu the Femoral Artery of a Cat The first efforts to treat canine heart- in 1933 in Romania and by W.H. Wright worm disease date back to the 1920s. Dr. and P.C. Underwood in 1934 in the USA. Page 26 Nelson referenced a review article by Dr. In 1949, I.C. Mark evaluated its use Quarterly Update Raffaele Roncalli, “Tracing the History of intraperitoneally.” What’s New From AHS? Heartworms: A 400 Year Perspective,” Continues on page 7 American Heartworm Society / PO Box 8266, Wilmington, DE 19803-8266 Become an American Heartworm Society www.heartwormsociety.org / [email protected] fan on Facebook! Follow us on Twitter! OUR GENEROUS SPONSORS PLATINUM LEVEL PO Box 8266 Wilmington, DE 19803-8266 [email protected] www.heartwormsociety.org Mission Statement The mission of the American Heartworm Society is to lead the vet- erinary profession and the public in the understanding of heartworm disease.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Efficacy of Different Types of Therapy for COVID-19
    life Review Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review Anna Starshinova 1,*, Anna Malkova 2 , Ulia Zinchenko 3 , Dmitry Kudlay 4,5 , Anzhela Glushkova 6, Irina Dovgalyk 3, Piotr Yablonskiy 2,3 and Yehuda Shoenfeld 2,7,8 1 Almazov National Medical Research Centre, Head of the Research Department, 2 Akkuratov Str., 197341 Saint-Petersburg, Russia 2 Medical Department, Saint Petersburg State University, 199034 Saint-Petersburg, Russia; [email protected] (A.M.); [email protected] (P.Y.); [email protected] (Y.S.) 3 St. Petersburg Research Institute of Phthisiopulmonology, 199034 Saint-Petersburg, Russia; [email protected] (U.Z.); [email protected] (I.D.) 4 NRC Institute of Immunology FMBA of Russia, 115478 Moscow, Russia; [email protected] 5 Medical Department, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia 6 V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology, 192019 Saint Petersburg, Russia; [email protected] 7 Ariel University, Kiryat HaMada 3, Ariel 40700, Israel 8 Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer 5265601, Israel * Correspondence: [email protected]; Tel.: +7-9052043861 Citation: Starshinova, A.; Malkova, Abstract: A new coronavirus disease (COVID-19) has already affected millions of people in 213 coun- A.; Zinchenko, U.; Kudlay, D.; tries. The possibilities of treatment have been reviewed in recent publications but there are many Glushkova, A.; Dovgalyk, I.; controversial results and conclusions. An analysis of the studies did not reveal a difference in Yablonskiy, P.; Shoenfeld, Y. Efficacy mortality level between people treated with standard therapy, such as antiviral drugs and dexam- of Different Types of Therapy for ethasone, and new antiviral drugs/additional immune therapy.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,173.403 B2 Rosentel, Jr
    USOO9173403B2 (12) United States Patent (10) Patent No.: US 9,173.403 B2 Rosentel, Jr. et al. (45) Date of Patent: Nov. 3, 2015 (54) PARASITICIDAL COMPOSITIONS FOREIGN PATENT DOCUMENTS COMPRISING MULTIPLE ACTIVE AGENTS, BR PIO403620 A 3, 2006 METHODS AND USES THEREOF EP 83.6851 A 4f1998 GB 2457734 8, 2009 (75) Inventors: Joseph K. Rosentel, Jr., Johns Creek, WO WO 98,17277 4f1998 GA (US); Monica Tejwani, Monmouth WO WO O2/O94233 11, 2002 WO WO2004/O16252 2, 2004 Junction, NJ (US); Arima Das-Nandy, WO WO 2007/O18659 2, 2007 Titusville, NJ (US) WO WO 2008/O3O385 3, 2008 WO 2008/136791 11, 2008 (73) Assignee: MERLAL, INC., Duluth, GA (US) WO WO 2009/O18198 2, 2009 WO WO 2009/027506 3, 2009 WO 2009/112837 9, 2009 (*) Notice: Subject to any disclaimer, the term of this WO WO 2010/026370 3, 2010 patent is extended or adjusted under 35 WO WO2010.109214 9, 2010 U.S.C. 154(b) by 100 days. OTHER PUBLICATIONS (21) Appl. No.: 13/078,496 Notice of Opposition in the matter of New Zealand Patent Applica (22) Filed: Apr. 1, 2011 tion 595934 in the name of Norbrook Laboratories Limited and Opposition thereto by Merial Limited dated Jun. 28, 2014. (65) Prior Publication Data First Supplementary Notice of Opposition in the matter of New Zealand Patent Application 595934 in the name of Norbrook Labo US 2011 FO245191 A1 Oct. 6, 2011 ratories Limited and Opposition thereto by Merial Limited dated Aug. 28, 2014. Second Supplementary Notice of Opposition in the matter of New Related U.S.
    [Show full text]
  • EFFECTS of DRUGS UPON SCOLICES and DAUGHTER CYSTS of Title ECHINOCOCCUS MULTILOCULARIS in VITRO
    STUDIES ON ECHINOCOCCOSIS XVI : EFFECTS OF DRUGS UPON SCOLICES AND DAUGHTER CYSTS OF Title ECHINOCOCCUS MULTILOCULARIS IN VITRO Author(s) SAKAMOTO, Tsukasa; YAMASHITA, Jiro; OHBAYASHI, Masashi; ORIHARA, Miyoji Citation Japanese Journal of Veterinary Research, 13(4), 127-136 Issue Date 1965-12 DOI 10.14943/jjvr.13.4.127 Doc URL http://hdl.handle.net/2115/1830 Type bulletin (article) File Information KJ00003418286.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP STUDIES ON ECHINOCOCCOSIS XVI EFFECTS OF DRUGS UPON SCOLICES AND DAUGHTER CYSTS OF ECHINOCOCCUS MULTILOCULARIS IN VITRO Tsukasa SAKA:"I0TO, liro YA:VIASHITA Masashi OHBA YASHI and Miyoji ORIHARA Dej)artment of Parasitology Faculty of Veterinary i\fedicine Hokkaido Unil1ersity, Sapporo, Japan (Received for publication, October 30, 1965) INTRODUCTION Many investigators have conducted experiments to treat human cases of echinococcosis with drugs which were known to be effective against other parasites. They, however, have failed to establish the efficacy of any drugs against the disease. The authors also have studied the potential of various anthelmintic drugs using mice infected artificially with Echinococcus multilocularis, but to date no drug effective against the disease has been found. nEVE (1926, '28) and COUTELEN (1927, '27) observed the vesicular development of the scolex of E. granulosus using media consisting mainly of hydatid fluid, and S:V1YTH (1962), WEBSTER & CAMERON (196:3) and SCHWABE et al. (1963) observed recently the vesicular development using media composed of both natural and synthetic substances. On the other hand, RAUSCH & lENTOFT (1957) observed in vitro the propagation of the larval E. multilocularis through the exogeneous budding of new vesicles.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios Et Al
    US 20060078604A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios et al. (43) Pub. Date: Apr. 13, 2006 (54) TRANSDERMAL DRUG DELIVERY DEVICE Related U.S. Application Data INCLUDING AN OCCLUSIVE BACKING (60) Provisional application No. 60/616,861, filed on Oct. 8, 2004. (75) Inventors: David Kanios, Miami, FL (US); Juan A. Mantelle, Miami, FL (US); Viet Publication Classification Nguyen, Miami, FL (US) (51) Int. Cl. Correspondence Address: A 6LX 9/70 (2006.01) DCKSTEIN SHAPRO MORN & OSHINSKY (52) U.S. Cl. .............................................................. 424/449 LLP (57) ABSTRACT 2101 L Street, NW Washington, DC 20037 (US) A transdermal drug delivery system for the topical applica tion of one or more active agents contained in one or more (73) Assignee: Noven Pharmaceuticals, Inc. polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can (21) Appl. No.: 11/245,180 control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmis (22) Filed: Oct. 7, 2005 sion rate of the polymeric backing layer. Patent Application Publication Apr. 13, 2006 Sheet 1 of 2 US 2006/0078604 A1 Fis ZZZZZZZZZZZZZZZZZZZ :::::::::::::::::::::::::::::::: Patent Application Publication Apr. 13, 2006 Sheet 2 of 2 US 2006/0078604 A1 3. s s 3. a 3 : 8 g US 2006/0078604 A1 Apr. 13, 2006 TRANSIDERMAL DRUG DELVERY DEVICE 0008. In the “classic' reservoir-type device, the active INCLUDING AN OCCLUSIVE BACKING agent is typically dissolved or dispersed in a carrier to yield a non-finite carrier form, Such as, for example, a fluid or gel.
    [Show full text]
  • Studies on Endemic Hookworm: 2. Comparison of the Efficacy of Anthelmintics in Taiwan and Liberia
    CJap. J. Parasit., Vol. 19, No. 5, 523-536, 1970] Studies on endemic hookworm: 2. Comparison of the efficacy of anthelmintics in Taiwan and Liberia Hsien-Chen HSIEH Department of Parasitology, Kaohsiung Medical College, Taiwan Republic of China (Received for publication ; August 18, 1970) Along with development of vaccination and Octylchloresorcinol (70 parts) and Octylreso- improvement of sanitation, searches for safe, rcinol (30 parts)] by Yamasaki et al. (1954). effective and cheap anti-hookworm drugs Since 1959, in Taiwan, the author and his have remained an important part of research co-wrorkers have evaluated the anthelmintic on endemic hookworm. activity of l-bromo-2-naphthol (Hsieh et al., Following experimental work by Perroncito 1960 a; Hsieh & Chen, 1965), piperazine (1879-1880) and clinical trials by Bozzolo & compounds (Brown et al., 1959 ; Hsieh et al., Pagliani (1880) in Italy, thymol, a phenolic 1961c, 1965), tetrachlorethylene (Hsieh et al., compound obtained from the aromatic oils 1960 a; Brown et al., 1959; Hsieh et al., of Thymus vulgaris, was found to be useful 1961c; Hsieh & Chen, 1965), bephenium against hookworm. It wras, however, unplea hydroxynaphthoate (Hsieh, 1959 ; Hsieh et sant to take and rather toxic. As indicated al., 1960b, 1961 be; Hsieh & Chen, 1965), in the Bibliography of Hookworm Disease stilbazium iodide (Hsieh et al., 1963 a), tri- published by the Rockefeller Foundation in chlorophenol piperazine (Hsieh et al., 1963 b), 1922 and the Bibliography of Hookworm thiabendazole (Hsieh, 1963) and phenylene- Disease (Ancylostomiasis) published by the diisothiocyanate (Hsieh et al., 1970), dithia- World Health Organization in 1965, the zanine iodide (Brown et al., 1959), ascaridol therapeutic efficacy of more than 50 drugs (Brown et al., 1959), and pyrvinium pamoate against hookworm had been tested by 1962.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • The Action of Chlorphenesin Carbamate on the Frog Spinal Cord
    Japan. J. Pharmacol. 30, 29-36 (1980) 29 THE ACTION OF CHLORPHENESIN CARBAMATE ON THE FROG SPINAL CORD Hironaka AIHARA, Michio KURACHI, Sadao NAKANE, Michitada SASAJIMA and Masahiro OHZEKI Research Laboratories, Taisho Pharmaceutical Co., Ltd., Yoshino-cho1-403, Omiya, Saitama 330, Japan Accepted September 10, 1979 Abstract-Studies were carried out to elucidate the mechanism of action of chlor- phenesin carbamate (CPC) and to compare the effect of the drug with that of mephenesin on the isolated bullfrog spinal cord. Ventral and dorsal root potentials were recorded by means of the sucrose-gap method. CPC caused marked hyperpolarizations and depressed spontaneous activities in both of the primary afferent terminals (PAT) and motoneurons (MN). These hyperpolarizations were observed even in high-Mg" and Ca2+-freeRinger's solution, suggesting that CPC has direct actions on PAT and MN. Various reflex potentials (dorsal and ventral root potentials elicited by stimulating dorsal and ventral root, respectively) tended to be depressed by CPC as well as by mephenesin. Excitatory amino acids (L-aspartic acid and L-glutamic acid) caused marked depolarizations in PAT and MN, and increased the firing rate in MN. CPC did not modify the depolarization but abolished the motoneuron firing induced by these amino acids. However, mephenesin reduced both the depolarization and the motoneuron firing. The dorsal and ventral root potentials evoked by tetanic stimu- lation (40 Hz) of the dorsal root were depressed by the drugs. These results indicate that CPC has an apparent depressing action on the spinal neuron, and this action may be ascribed to the slight hyperpolarization and/or the prolongation of refractory period.
    [Show full text]
  • MASENZ DANYA GROUP SL, Is an EUROPEAN Pharmaceutical Company Based in BARCELONA, Spain
    CATALOGUE ABOUT US MASENZ DANYA GROUP SL, is an EUROPEAN pharmaceutical company based in BARCELONA, Spain. Specializing in research, sourcing and distribution of raw materials, MASENZ DANYA GROUP SL is progressing serenely each year through distribution agreements signed with companies around the world; concerned about the quality of our products and our organization, MASENZ has consolidated a strong EUROPEAN market position. We are now developing at the international and thus carry more than 40% of our turnover from exports to over 30 countries in Europe, Asia, Africa and America. We meet the specific demands of our customers by seeking new products and new suppliers worldwide. Masenz Danya Group SL +34 933 484 605 Narcís Monturiol 37, 08960 Barcelona, www.masenzgroup.com 2 Ciprofloxacin CEP API Citalopram Citicoline Clarithromycin Clindamycin Palmitate G Clomifene Gabapentin Clonazepam Gentamycine CEP A Clonidine Glibenclamide Acetazolamide Clopidogrel bisulphate Gliclazide Acyclovir CEP Clozapine Glimepiride Adrenaline Colchicine Glipizide Alendronate Sodium Cobalamine Glucosamine Sulphate Ambroxol CEP Cyproheptadine Guaifenesin Amlodipine Besylate CEP D H Alprazolam Desloratadine CEP Haloperidol Aluminium Hydroxide- Magnesium Desmopressin Acetate Hydrochlorothiazide CEP Amiodarone Hcl Dexchlorpheniramine Maleate Hydroxyzine Hcl Amitriptylline Hcl Dexlansoprazole Hydroxocobalamine Amoxicilline CEP Dextrometorphane I Aripiprazole CEP Diclofenac Ibuprofen CEP Atenolol Diltiazem Imipenem Atorvastatin Digoxine Irbesartan B Diphenhydramine
    [Show full text]
  • 118 Part 520—Oral Dosage Form New Animal Drugs
    § 516.1318 21 CFR Ch. I (4–1–12 Edition) associated with Flavobacterium 520.45a Albendazole suspension. columnare. 520.45b Albendazole paste. (iii) Limitations. Feed containing 520.48 Altrenogest. florfenicol shall not be fed to catfish 520.62 Aminopentamide hydrogen sulphate tablets. for more than 10 days. Following ad- 520.82 Aminopropazine fumarate oral dosage ministration, fish should be reevalu- forms. ated by a licensed veterinarian before 520.82a Aminopropazine fumarate tablets. initiating a further course of therapy. 520.82b Aminopropazine fumarate, neomy- A dose-related decrease in cin sulfate tablets. hematopoietic/lymphopoietic tissue 520.88 Amoxicillin oral dosage forms. may occur. The time required for 520.88a Amoxicillin trihydrate film-coated hematopoietic/lymphopoietic tissues to tablets. 520.88b Amoxicillin trihydrate for oral sus- regenerate was not evaluated. The ef- pension. fects of florfenicol on reproductive per- 520.88c Amoxicillin trihydrate oral suspen- formance have not been determined. sion. Feeds containing florfenicol must be 520.88d Amoxicillin trihydrate soluble pow- withdrawn 12 days prior to slaughter. der. Federal law limits this drug to use 520.88e Amoxicillin trihydrate boluses. under the professional supervision of a 520.88f Amoxicillin trihydrate tablets. licensed veterinarian. The expiration 520.88g Amoxicillin trihydrate and clavulanate potassium film-coated tab- date of veterinary feed directives lets. (VFDs) for florfenicol must not exceed 520.88h Amoxicillin trihydrate and 15 days from the date of prescribing. clavulanate potassium for oral suspen- VFDs for florfenicol shall not be re- sion. filled. See § 558.6 of this chapter for ad- 520.90 Ampicillin oral dosage forms. ditional requirements. 520.90a Ampicillin capsules.
    [Show full text]